The price-to-earnings ratio for Gyre Therapeutics Inc (NASDAQ: GYRE) is above average at 216.49x. The 36-month beta value for GYRE is also noteworthy at 1.82. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GYRE is 15.88M, and at present, short sellers hold a 14.91% of that float. The average trading volume of GYRE on May 22, 2025 was 159.07K shares.
GYRE) stock’s latest price update
Gyre Therapeutics Inc (NASDAQ: GYRE)’s stock price has gone decline by -9.04 in comparison to its previous close of 11.40, however, the company has experienced a -0.19% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-05-09 that Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025 Received IND approval from China’s National Medical Products Administration (“NMPA”) for a new indication of pirfenidone to treat radiation-induced lung injury (“RILI”), with or without immune-related pneumonitis (“CIP”), marking Gyre’s first entry into oncology supportive care space Initiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialists Nintedanib remains on track for commercialization in May 2025, expanding IPF treatment options across our physician network $51.3 million in cash, cash equivalents, and short and long-term deposits as of March 31, 2025 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. “This quarter marked a meaningful step forward in expanding our market presence, particularly in the liver space,” said Han Ying, Ph.D.
GYRE’s Market Performance
GYRE’s stock has fallen by -0.19% in the past week, with a monthly rise of 20.02% and a quarterly drop of -17.44%. The volatility ratio for the week is 6.30% while the volatility levels for the last 30 days are 7.43% for Gyre Therapeutics Inc The simple moving average for the past 20 days is 4.37% for GYRE’s stock, with a -9.63% simple moving average for the past 200 days.
Analysts’ Opinion of GYRE
Stephens, on the other hand, stated in their research note that they expect to see GYRE reach a price target of $19, previously predicting the price at $18. The rating they have provided for GYRE stocks is “Overweight” according to the report published on April 29th, 2021.
Piper Sandler gave a rating of “Overweight” to GYRE, setting the target price at $15 in the report published on February 10th of the previous year.
GYRE Trading at 12.04% from the 50-Day Moving Average
After a stumble in the market that brought GYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.42% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 6.30%, as shares surge +12.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.63% lower at present.
During the last 5 trading sessions, GYRE fell by -0.19%, which changed the moving average for the period of 200-days by -3.89% in comparison to the 20-day moving average, which settled at $9.94. In addition, Gyre Therapeutics Inc saw -14.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GYRE starting from Ma Songjiang, who sale 2,000 shares at the price of $11.31 back on May 16 ’25. After this action, Ma Songjiang now owns 2,816,824 shares of Gyre Therapeutics Inc, valued at $22,620 using the latest closing price.
Ma Songjiang, the President of Gyre Therapeutics Inc, sale 2,000 shares at $11.11 during a trade that took place back on May 19 ’25, which means that Ma Songjiang is holding 2,814,824 shares at $22,220 based on the most recent closing price.
Stock Fundamentals for GYRE
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.96 for the gross margin
The net margin for Gyre Therapeutics Inc stands at 0.14. The total capital return value is set at 0.09. Equity return is now at value 11.62, with 5.76 for asset returns.
Based on Gyre Therapeutics Inc (GYRE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -4.2.
Currently, EBITDA for the company is 17.82 million with net debt to EBITDA at -1.2. When we switch over and look at the enterprise to sales, we see a ratio of 8.94. The receivables turnover for the company is 4.99for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.
Conclusion
In summary, Gyre Therapeutics Inc (GYRE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
